MS clinical trial design for the future. - Wikidata - awgldk - TriplyDB

MS clinical trial design for the future.

MS clinical trial design for the future.

http://www.wikidata.org/entity/Q40934002

about

MS clinical trial design for the future.

http://www.wikidata.org/entity/Q40934002

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

MS clinical trial design for the future.

@en

type

label

MS clinical trial design for the future.

@en

prefLabel

MS clinical trial design for the future.

@en

P1433

Q40934002-B5D41A03-0D60-4876-8C2D-1EA17F9A2371

P1476

Q40934002-E076AEFD-0E55-4A6E-9019-839D3B1AD98D

P2093

Q40934002-247AEE69-A899-429D-9E12-C03798542B14

P2860

Q40934002-0F78373F-D8F9-489D-9EF6-1D6105D4514F

Q40934002-1C1078C2-41FD-45BF-8E0E-CC7E1E7F52D1

Q40934002-20DB11DF-4FDD-4B0D-8291-3982DD494729

Q40934002-241666AE-2DB0-4E5E-9A06-BED793C7A4CD

Q40934002-26F26C09-11A9-4880-BF9B-5E5D8010C6E8

Q40934002-28536FD1-4444-4D4A-AA71-897B19F3B279

Q40934002-310B2DC3-583C-4224-9705-8D978C92F004

Q40934002-497FBA5D-E6AA-4927-A6D5-0ED89E226814

Q40934002-4C69134B-396C-4C1A-9FEF-6405955C8850

Q40934002-4DDD99AE-D2D8-4505-B5CD-C41968B033A5

P304

Q40934002-37718540-33A0-4FE7-BB76-A9B9013F3289

P31

Q40934002-9D86BDDF-C30B-4158-9101-CDFE90CAEA79

P356

Q40934002-7C113DC2-9E8C-4BD1-86C5-65D5D6141DF8

P433

Q40934002-0F1DA5CE-AEDB-4763-806C-45CC7B856055

P478

Q40934002-FFB5667B-4059-4DE2-A3A2-951C99203118

P577

Q40934002-7E3128B2-A2F8-46DD-8AB7-C1AC428FBC36

P698

Q40934002-C76FB03E-4086-4110-8C96-6FF7FBC0FD1A

P356

135245859600100623

P1433

Multiple Sclerosis Journal

P1476

MS clinical trial design for the future.

@en

P2093

D E Goodkin

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Nonparametric Estimation from Incomplete Observations

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Interferon beta-1b.

Immune-mediated demyelination.

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis.

Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.

Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.

P304

393-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/135245859600100623

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

1996-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9345425

http://www.w3.org/2001/XMLSchema#string